Osteopontin is a prognostic biomarker in non-small cell lung cancer

Rud, Ane Kongsgaard; Boye, Kjetil; Øijordsbakken, Miriam; Lund‐Iversen, Marius; Halvorsen, Ann Rita; Solberg, Steinar; Berge, G; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild Mari

doi:10.1186/1471-2407-13-540

Cited by 46 publications

(50 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In gastric cancer (Tang et al 2008), a similar importance was found between osteopontin expression and clinical stages, nodal metastasis, and distant metastasis. Emerging data support a role for osteopontin as a potential prognostic factor in various human tumors, including non-small cell cancer (Rud et al 2013), hepatocellular carcinoma (Zhang et al 2012), and prostate cancer (Forootan et al 2006). However, the correlation between osteopontin expression and survival is controversial in cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

Huang

Qian

et al. 2014

J Histochem Cytochem.

View full text Add to dashboard Cite

SummaryRadiotherapy is the first-line treatment for all stages of cervical cancer, whether it is used for radical or palliative therapy. However, radioresistance of cervical cancer remains a major therapeutic problem. Consequently, we explored if E-cadherin (a marker of epithelial-mesenchymal transition) and osteopontin could predict radioresistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC). Patients were retrospectively reviewed and 111 patients divided into two groups (radiation-resistant and radiation-sensitive groups) according to progression-free survival (PFS). In pretreated paraffin-embedded tissues, we evaluated E-cadherin and osteopontin expression using immunohistochemical staining. The percentage of patients with high osteopontin but low E-cadherin expression in the radiation-resistant group was significantly higher than those in the radiation-sensitive group (p<0.001). These patients also had a lower 5-year PFS rate (p<0.001). Our research suggests that high osteopontin but low E-cadherin expression can be considered as a negative, independent prognostic factor in patients with LACSCC ([Hazard ratios (95% CI) 6.766 (2.940, 15.572)], p<0.001). (J Histochem Cytochem 63:88-98, 2015)

show abstract

Section: Discussionmentioning

confidence: 99%

Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

Huang

Qian

et al. 2014

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…An association of multifocal brain involvement with inferior outcome has previously been reported [37,38]. Moreover, a correlation of increased circulating OPN levels and increased OPN expression by tumour cells with an unfavourable prognosis was found in other human malignancies [20][21][22].…”

Section: Discussionmentioning

confidence: 98%

“…High OPN expression is associated with progression, metastatic spread, and poor prognosis in many malignancies. Several studies in different human malignancies identified OPN as suitable diagnostic and prognostic biomarker [17][18][19][20][21][22][23][24]. In PCNSL, osteopontin (also known as secreted phosphoprotein 1, SPP1) is one of the most differentially up-regulated genes as compared to both nodal and extranodal non-CNS diffuse large B-cell lymphoma (DLBCL) [25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

et al. 2016

View full text Add to dashboard Cite

Central nervous system lymphoma (CNSL) is diagnostically challenging. The identification of reliable and easy to measure biomarkers is desirable to facilitate diagnosis. Here, we evaluated the value of cerebrospinal fluid (CSF) osteopontin (OPN) as a diagnostic biomarker for CNSL. OPN concentrations in CSF from 37 patients with CNSL (29 with primary CNSL and 8 with secondary CNS involvement of systemic lymphoma) and 36 controls [6 patients with inflammatory CNS disease other than multiple sclerosis (MS), 8 with MS, 9 with glioblastoma (GBM) and 13 healthy controls] were determined using an enzyme-linked immunosorbent assay. Non-parametric tests and receiver operating characteristic (ROC) curves were performed for determination of diagnostic accuracy. Median CSF OPN level in all CNSL patients was 620 ng/mL and higher than in patients with inflammatory CNS disease (356 ng/mL); P < .05, MS (163 ng/mL); P < .01, GBM (41 ng/mL); P < .01, or healthy controls (319 ng/mL); P < .01. The area under the ROC curve was 0.865 [95 % confidence interval (CI) 0.745-0.985] for differentiating CNSL and patients with inflammatory CNS disease; 0.956 (95 % CI 0.898-1.000) for CNSL and MS patients; 0.988 (95 % CI 0.964-1.000) for CNSL and GBM patients, and 0.915 (95 % CI 0.834-0.996) for CNSL patients and healthy controls. In multivariate analysis, high CSF OPN level was associated with shorter progression-free (HR 1.61, 95 % CI 1.13-2.31; P = .009) and overall survival (HR 1.52, 95 % CI 1.04-2.21; P = .029). CSF OPN is a potential biomarker in CNSL.

show abstract

“…In human malignant melanoma, OPN expression is significantly associated with reduced relapse-free survival and additional histological parameters that are associated with poor clinical outcome [7,24,29,33]. OPN is a prognostic marker in a variety of cancers [30,[39][40][41]. In metastatic and primary melanomas, OPN has also been suggested to be a novel promising biomarker for the detection of metastases in patients with primary melanomas [24,[42][43][44][45].…”

Section: Discussionmentioning

confidence: 99%

The role of osteopontin expression in melanoma progression

et al. 2015

View full text Add to dashboard Cite

It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer progression. In addition to multiple intra-and extracellular functions, it facilitates migration of tumor cells, has crucial role in cell adhesion and is associated with increased metastasis formation. In previous studies, we performed global gene-expression profiling on a series of primary melanoma samples and found that OPN was significantly overexpressed in ulcerated melanomas. The major purpose of this study was to define OPN expression in primary melanomas with differing biological behaviours. OPN mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests were used for survival analysis. Greater than 50% of the tissues exhibited high protein expression that was significantly associated with tumor thickness and metastasis. OPN mRNA expression was significantly increased in thicker melanomas and lesions with an ulcerated surface. Increased expression was primarily detected in advanced-stage tumors. A multivariate Cox regression analysis revealed that high OPN expression, tumor thickness, and metastasis were significantly associated with reduced relapse-free survival. In summary, high OPN mRNA and protein expression were associated with a less favourable clinical outcome of primary melanoma patients. We determined that OPN is a significant predictive factor for the survival of primary melanoma patients. Based on our and others data the high expression of OPN may have a crucial stimulatory role in tumor progression and metastasis formation, thus, have been proposed as potential targets for cancer diagnosis and therapy.3

show abstract

Osteopontin is a prognostic biomarker in non-small cell lung cancer

Cited by 46 publications

References 30 publications

Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

Aberrant Expression of Osteopontin and E-Cadherin Indicates Radiation Resistance and Poor Prognosis for Patients with Cervical Carcinoma

Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma

The role of osteopontin expression in melanoma progression

Contact Info

Product

Resources

About